Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fassbender, K.
Right arrow Articles by Lütjohann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fassbender, K.
Right arrow Articles by Lütjohann, D.
Related Collections
Right arrow Alzheimer's disease

Neurology 2002;59:1257-1258
© 2002 American Academy of Neurology
Brief Communications

Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide

K. Fassbender, MD, M. Stroick, T. Bertsch, MD, A. Ragoschke, S. Kuehl, S. Walter, MD, J. Walter, K. Brechtel, F. Muehlhauser, MD, K. von Bergmann, MD and D. Lütjohann, PhD

From the Department of Neurology (Drs. Fassbender and Muehlhauser, A. Ragoschke, S. Kuehl, S. Walter, J. Walter, and K. Brechtel), University of Goettingen; Departments of Clinical Chemistry (Dr. Bertsch) and Neurology (M. Stroik), Clinic Mannheim, University of Heidelberg; and Department of Clinical Pharmacology (Drs. von Bergmann and Lütjohann), University of Bonn, Germany.

Address correspondence and reprint requests to Prof. K. Fassbender, Department of Neurology, University of Goettingen, Robert Koch Str. 40, 37075 Goettingen, Germany; e-mail: klaus.fassbender{at}med.uni-goettingen.de

Cerebral cholesterol metabolism has been linked with production of amyloid peptide (Aß) crucial in AD. The association between use of cholesterol-lowering drugs (statins) and AD disease is currently being intensely discussed. In this case-control study on elderly nondemented subjects, the authors provide the first evidence that statins in clinically relevant dosages indeed affect cerebral cholesterol metabolism. However, these changes were not associated with altered intrathecal secretion of Alzheimer Aß.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
K. P Padala, P. R Padala, and J. F Potter
Simvastatin-Induced Decline in Cognition
Ann. Pharmacother., October 1, 2006; 40(10): 1880 - 1883.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
I Masse, R Bordet, D Deplanque, A Al Khedr, F Richard, C Libersa, and F Pasquier
Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, December 1, 2005; 76(12): 1624 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Bernick, R. Katz, N. L. Smith, S. Rapp, R. Bhadelia, M. Carlson, L. Kuller, and for the Cardiovascular Health Study Collaborative
Statins and cognitive function in the elderly: The Cardiovascular Health Study
Neurology, November 8, 2005; 65(9): 1388 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 AM J ALZHEIMERS DIS OTHER DEMENHome page
A. B. Reiss
Cholesterol and apolipoprotein E in Alzheimer's disease
American Journal of Alzheimer's Disease and Other Dementias, March 1, 2005; 20(2): 91 - 96.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
A. M. Fagan, E. Christopher, J. W. Taylor, M. Parsadanian, M. Spinner, M. Watson, J. D. Fryer, S. Wahrle, K. R. Bales, S. M. Paul, et al.
ApoAI Deficiency Results in Marked Reductions in Plasma Cholesterol But No Alterations in Amyloid-{beta} Pathology in a Mouse Model of Alzheimer's Disease-Like Cerebral Amyloidosis
Am. J. Pathol., October 1, 2004; 165(4): 1413 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
I. Bjorkhem and S. Meaney
Brain Cholesterol: Long Secret Life Behind a Barrier
Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 806 - 815.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
C. Bate, M. Salmona, L. Diomede, and A. Williams
Squalestatin Cures Prion-infected Neurons and Protects Against Prion Neurotoxicity
J. Biol. Chem., April 9, 2004; 279(15): 14983 - 14990.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
K. Hoglund, O. Wiklund, H. Vanderstichele, O. Eikenberg, E. Vanmechelen, and K. Blennow
Plasma Levels of {beta}-Amyloid(1-40), {beta}-Amyloid(1-42), and Total {beta}-Amyloid Remain Unaffected in Adult Patients With Hypercholesterolemia After Treatment With Statins
Arch Neurol, March 1, 2004; 61(3): 333 - 337.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Zacco, J. Togo, K. Spence, A. Ellis, D. Lloyd, S. Furlong, and T. Piser
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity
J. Neurosci., December 3, 2003; 23(35): 11104 - 11111.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. L. Sparks and B. G. Schreurs
Trace amounts of copper in water induce {beta}-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease
PNAS, September 16, 2003; 100(19): 11065 - 11069.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
H. Fukumoto, M. Tennis, J. J. Locascio, B. T. Hyman, J. H. Growdon, and M. C. Irizarry
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid {beta}-Protein Levels
Arch Neurol, July 1, 2003; 60(7): 958 - 964.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.